---
title: "Propanc Biopharma signs MOU with Avance Clinical for PRP Phase 1b trial delivery"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291933222.md"
description: "Propanc Biopharma signed an MOU with Avance Clinical to support the delivery of its Phase 1b first-in-human trial for PRP in patients with advanced solid tumors. The collaboration aims to accelerate development from first-in-human to proof-of-concept, leveraging Avance's early-phase oncology CRO services and Australia’s faster ethics pathway."
datetime: "2026-07-07T12:33:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291933222.md)
  - [en](https://longbridge.com/en/news/291933222.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291933222.md)
---

# Propanc Biopharma signs MOU with Avance Clinical for PRP Phase 1b trial delivery

-   Propanc Biopharma signed an MOU with Avance Clinical to support clinical delivery of its Phase 1b first-in-human trial of PRP. \* The trial targets patients with advanced solid tumors, with endpoints including safety, tolerability, pharmacokinetics, immunogenicity, and early activity. \* Parties plan to use the collaboration to accelerate PRP from first-in-human into proof-of-concept, subject to results. \* Avance Clinical will provide early-phase oncology CRO support, with the program expected to run through Australia’s faster ethics pathway and 43.5% R&D tax rebate. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070830PRIMZONEFULLFEED9758120) on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [PPCB.US](https://longbridge.com/en/quote/PPCB.US.md)
- [PPCBD.US](https://longbridge.com/en/quote/PPCBD.US.md)

## Related News & Research

- [Radiopharm Theranostics Reports Positive Results from RAD204 and RAD101 Trials](https://longbridge.com/en/news/293403693.md)
- [Pasithea Therapeutics posts investor presentation on PAS-004 MEK inhibitor program in NF1 and solid tumors](https://longbridge.com/en/news/293364949.md)
- [Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone | APVO Stock News](https://longbridge.com/en/news/293930096.md)
- [09:52 ETHoneyNaps Registers as Contract Research Organization (CRO), Accelerating AI-Powered Clinical Trial Analytics](https://longbridge.com/en/news/293943606.md)
- [07:03 ETTikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors](https://longbridge.com/en/news/293462444.md)